Chalkis Health Industry Co., Ltd (SHE:000972)
China · Delayed Price · Currency is CNY 3.880
+0.010 (0.26%)
May 8, 2026, 3:04 PM CST
Chalkis Health Industry Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 463.63 | 487.51 | 294.23 | 559.76 | 576.99 | 165.75 |
Other Revenue | 4.61 | 4.61 | 13.92 | 16.02 | 12.3 | 8.7 |
| 468.24 | 492.12 | 308.15 | 575.78 | 589.29 | 174.45 | |
Revenue Growth (YoY) | 74.98% | 59.70% | -46.48% | -2.29% | 237.79% | 659.61% |
Cost of Revenue | 659.87 | 670.42 | 531.35 | 430.61 | 434.61 | 180.74 |
Gross Profit | -191.62 | -178.31 | -223.2 | 145.17 | 154.68 | -6.29 |
Selling, General & Admin | 100.73 | 96.99 | 50.64 | 59.35 | 34.2 | 40.33 |
Research & Development | 0.69 | 0.9 | 1.98 | 0.73 | - | - |
Other Operating Expenses | 4.32 | 5.15 | 2.96 | 6.3 | 4.12 | 3.14 |
Operating Expenses | 99.76 | 97.06 | -23.79 | 80.8 | 100.73 | 74.89 |
Operating Income | -291.39 | -275.37 | -199.41 | 64.37 | 53.94 | -81.18 |
Interest Expense | -45.2 | -45.2 | -26.84 | -22.02 | -15.87 | -10.29 |
Interest & Investment Income | 0.36 | 0.36 | 0.32 | 1.91 | 0.84 | 0.1 |
Currency Exchange Gain (Loss) | -0.76 | -0.76 | 0.94 | 0.96 | 3.16 | -0.8 |
Other Non Operating Income (Expenses) | 2.28 | -0.06 | 0.55 | 1.34 | -11.03 | -7.87 |
EBT Excluding Unusual Items | -334.7 | -321.04 | -224.44 | 46.56 | 31.04 | -100.05 |
Gain (Loss) on Sale of Investments | - | - | - | - | -0 | - |
Gain (Loss) on Sale of Assets | 3.27 | 3.39 | 0.74 | 40.57 | 0.22 | 0.23 |
Asset Writedown | -12.69 | -12.69 | - | - | -1.66 | -2.51 |
Legal Settlements | -0.15 | -0.15 | -0.2 | -0.58 | -0.03 | - |
Other Unusual Items | 278.72 | 278.72 | -8.74 | 22.82 | 1.8 | -4.54 |
Pretax Income | -65.55 | -51.77 | -232.64 | 109.37 | 31.38 | -106.87 |
Income Tax Expense | 3.06 | 4.26 | 0.26 | 0.22 | 5.29 | 0 |
Earnings From Continuing Operations | -68.61 | -56.03 | -232.9 | 109.15 | 26.08 | -106.87 |
Minority Interest in Earnings | 10.01 | 9.8 | 2.12 | -0.91 | 0 | 0.06 |
Net Income | -58.61 | -46.23 | -230.78 | 108.24 | 26.09 | -106.81 |
Net Income to Common | -58.61 | -46.23 | -230.78 | 108.24 | 26.09 | -106.81 |
Net Income Growth | - | - | - | 314.94% | - | - |
Shares Outstanding (Basic) | 771 | 772 | 771 | 771 | 870 | 763 |
Shares Outstanding (Diluted) | 771 | 772 | 771 | 771 | 870 | 763 |
Shares Change (YoY) | -0.16% | 0.07% | -0.02% | -11.27% | 13.96% | -2.44% |
EPS (Basic) | -0.08 | -0.06 | -0.30 | 0.14 | 0.03 | -0.14 |
EPS (Diluted) | -0.08 | -0.06 | -0.30 | 0.14 | 0.03 | -0.14 |
EPS Growth | - | - | - | 367.67% | - | - |
Free Cash Flow | 348.24 | 189.64 | -133.24 | -397.17 | 183.66 | -200.69 |
Free Cash Flow Per Share | 0.45 | 0.25 | -0.17 | -0.52 | 0.21 | -0.26 |
Gross Margin | -40.92% | -36.23% | -72.43% | 25.21% | 26.25% | -3.60% |
Operating Margin | -62.23% | -55.96% | -64.71% | 11.18% | 9.15% | -46.53% |
Profit Margin | -12.52% | -9.40% | -74.89% | 18.80% | 4.43% | -61.23% |
Free Cash Flow Margin | 74.37% | 38.54% | -43.24% | -68.98% | 31.17% | -115.04% |
EBITDA | -253.89 | -238.05 | -162.82 | 105.27 | 98.72 | -35.54 |
EBITDA Margin | -54.22% | -48.37% | -52.84% | 18.28% | 16.75% | -20.37% |
D&A For EBITDA | 37.5 | 37.32 | 36.6 | 40.9 | 44.78 | 45.64 |
EBIT | -291.39 | -275.37 | -199.41 | 64.37 | 53.94 | -81.18 |
EBIT Margin | -62.23% | -55.96% | -64.71% | 11.18% | 9.15% | -46.53% |
Effective Tax Rate | - | - | - | 0.20% | 16.86% | - |
Revenue as Reported | 492.12 | 492.12 | 308.15 | 575.78 | 589.29 | 174.45 |
Advertising Expenses | - | 0.47 | 0.66 | 0.63 | 0.05 | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.